Fat jabs boost Applied Nutrition as Brits are less 'secretive' about weight-loss medications

Fat jabs boost Applied Nutrition as Brits are less 'secretive' about weight-loss medications

Updated: 06:33 EST, 16 November 2026 Protein shake maker Applied Nutrition has said that fat jabs are boosting demand for its products as Brits have become less ‘secretive’ about taking the medication.It has launched a ‘GLP1-Friendly Range’ in recent weeks, including protein shake sachets starting from £2, as well as other supplements including collagen and creatine.Profits at the Coleen Rooney-backed retailer leapt 43.9 per cent to £41 million for the year to July 31 while sales jumped by 50.9 per cent.Its boss Thomas Ryder, a Liverpudlian former scaffolder who set up the business in 2014, said that there is ‘no sign of [demand for weight-loss medication] slowing down’.Weight-loss drugs, medically known as GLP-1s, can cause a loss of muscle mass alongside fat, so doctors advise that users take up strength training and eat enough protein to combat the unhelpful side effects. TV personality Coleen Rooney is one of the investors in the protein company and has a range of products.Ryder is hopeful that sales of his products will be boosted by the rollout of the medication in a pill form.More than 6.3 per cent of households in Britain now include at least one person using the medication, according to research by Worldpanel by Numerator.Attitudes towards taking the drugs have changed over the past two years, Ryder says.He said: ‘We were very hesitant to put ‘GLP-1’ anywhere near a product because it was quite secretive. It was quite taboo. People didn't openly talk about it. But then fast forward two years, and people are openly speaking about it.‘I wouldn't necessarily say they're proud of it, but they're very transparent with it, and you know some people are getting amazing results from it.’Ryder said he and his colleagues took the jab for several weeks earlier this year to see what the negative symptoms were and what products could be suited to users. As the medication makes it harder to eat, they turned to hydration and protein products to refuel. A collaboration with Coleen Rooney, who is an investor in the business, has also helped the business appeal to more women.Ryder said: ‘We did want to become more, I would say, more popular with the female audience, and I think bringing Coleen in onboard with us has helped that massively. She has closed the gap from the male to female.’The group is known for its collaborations, which currently include Slush Puppie, Swizzels Love Hearts and Vimto. Bosses believe this has helped them appeal to younger users.Young people are continuing to swap ‘night clubs for run clubs,’ Ryder said, with consumers prioritising their health even amid cost of living pressures.But London-listed shares fell 3 per cent on Monday morning as investors fretted about higher protein costs weighing on margins.Adam Vetesse, market analyst at investment platform Etoro, said: ‘Higher whey protein costs and a greater contribution from lower-margin US sales are expected to nibble at profitability in the year ahead, even as revenue continues to rise. Heavy investment in stock to support the growth has also hit cash conversion.‘In short, the growth story remains intact, but the market is now asking how much of that growth will drop through to the bottom line once the easy upgrades are behind it.’Applied Nutrition said that while whey protein prices had reached ‘unprecedented levels’, driven in part because of increased demand due to the GLP1 boom, inflation was cooling off.‘As those pressures will end, we’ll start hopefully being able to pass that on to consumers next year,’ Ryder said.It is also pursuing international growth after paying £12m to acquire US sports nutrition manufacturer Nutrablend Group, including a warehouse in Buffalo, New York and two brands, Basic and GR8 Lifestyle.DIY INVESTING PLATFORMSAJ BellAJ BellEasy investing and ready-made portfoliosHargreaves LansdownHargreaves LansdownFree fund dealing and investment ideasinteractive investorinteractive investorFlat-fee investing from £4.99 per monthFreetradeFreetradeInvesting Isa now free on basic planTrading 212Trading 212Free share dealing and no account feeAffiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.Compare the best investing account for you

Original Source

Read the full article at Dailymail →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.